In this exclusive interview with Livewire, NDF Research Senior Analyst discusses ImpediMed (ASX: IPD), a company that has been one of the poster children of the Life Sciences sector on ASX over the last two years. Livewire is Australia’s source of financial intelligence - visit www.livewiremarkets.com. If you want to know why ASX-listed Life Sciences companies are worth taking a look at in 2016, consider ImpediMed (ASX: IPD), now a A$540m company. When I had lunch with CEO Rick Carreon and CFO CFO Morten Vigeland in mid-2013 their company was capitalised at a mere $20m or so. ImpediMed was arguably the world leader in medical devices using bioimpedance spectroscopy to noninvasively monitor the fluid status of patients. The company had gained FDA approval for L-Dex, a new generation diagnostic for lymphoedema, which can hit up to one in five women after breast cancer surgery. But before Rick Carreon, previously a successful Medtronic executive, ImpediMed hadn't figured out how to get paid for L-Dex. Rick and Morten shared with me their plans for fixing that problem and, sure enough, by September 2014, L-Dex had the needed reimbursement, not just for breast cancer but for all cancer-related lymphoedema. Every time our Life Sciences sector attracts a Rick Carreon to help it out - and he has been a generous supporter - we move to a higher level. Note - the usual disclaimers apply - click here.
1 Comment
3/2/2017 04:21:05 pm
I am very happy to find stuart roberts given discusses from exclusive interview and the details you should follow for having research on this blog. Then everything will be good and important to all of them.
Reply
Leave a Reply. |
Stuart RobertsSenior Analyst, NDF Research Archives
May 2018
Categories |